Pages that link to "Q42700685"
Jump to navigation
Jump to search
The following pages link to Julia Gee (Q42700685):
Displaying 50 items.
- Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization (Q24803435) (← links)
- ADAM metalloproteases and EGFR signalling (Q24803587) (← links)
- Extreme growth factor signalling can promote oestrogen receptor-alpha loss: therapeutic implications in breast cancer (Q24806505) (← links)
- Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models (Q24813647) (← links)
- TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence (Q28201559) (← links)
- Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells (Q28299546) (← links)
- Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets (Q28541545) (← links)
- Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. (Q34376333) (← links)
- Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. (Q34435089) (← links)
- ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. (Q34539617) (← links)
- Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. (Q34857146) (← links)
- The Biology of Antihormone Failure in Breast Cancer (Q35554875) (← links)
- Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1 (Q35558954) (← links)
- Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. (Q36110138) (← links)
- Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer (Q36172210) (← links)
- Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. (Q36236568) (← links)
- Overview of tyrosine kinase inhibitors in clinical breast cancer. (Q36236590) (← links)
- Development of strategies for the use of anti-growth factor treatments. (Q36236610) (← links)
- Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. (Q36236624) (← links)
- Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. (Q36236645) (← links)
- Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells (Q36393289) (← links)
- Evaluation of the current knowledge limitations in breast cancer research: a gap analysis (Q36678664) (← links)
- Growth factor receptor interplay and resistance in cancer (Q36720694) (← links)
- Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. (Q36720709) (← links)
- Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. (Q36720713) (← links)
- Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. (Q36814491) (← links)
- A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer. (Q36903310) (← links)
- Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells (Q37131348) (← links)
- Steroid hormone receptors and their clinical significance in cancer. (Q37268503) (← links)
- Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells. (Q37385287) (← links)
- Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro (Q37690245) (← links)
- A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer. (Q37929842) (← links)
- Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. (Q39352451) (← links)
- Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. (Q39872444) (← links)
- Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. (Q39880360) (← links)
- Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. (Q39906003) (← links)
- Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. (Q40074875) (← links)
- Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. (Q40259343) (← links)
- Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. (Q40342689) (← links)
- Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. (Q40355980) (← links)
- Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. (Q40383001) (← links)
- Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. (Q40394719) (← links)
- Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. (Q40514026) (← links)
- Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. (Q40628338) (← links)
- Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. (Q42437146) (← links)
- ONCOPOOL - a European database for 16,944 cases of breast cancer. (Q43265459) (← links)
- The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study. (Q43279359) (← links)
- BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer (Q43497738) (← links)
- Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer (Q43549612) (← links)
- Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer (Q43635626) (← links)